AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
AcelRx Pharmaceuticals Stock Performance
Shares of NASDAQ:ACRX remained flat at $0.23 during mid-day trading on Friday. 713,903 shares of the company were exchanged, compared to its average volume of 1,740,321. AcelRx Pharmaceuticals has a 1 year low of $0.16 and a 1 year high of $1.25. The company has a market cap of $33.73 million, a price-to-earnings ratio of -0.85 and a beta of 0.44. The company has a 50-day moving average price of $0.23 and a 200-day moving average price of $0.29.
AcelRx Pharmaceuticals (NASDAQ:ACRX - Get Rating) last issued its quarterly earnings results on Monday, May 16th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06). The business had revenue of $0.44 million during the quarter, compared to analysts' expectations of $0.50 million. During the same period in the prior year, the business earned ($0.08) EPS. On average, research analysts predict that AcelRx Pharmaceuticals will post -0.23 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Separately, StockNews.com started coverage on shares of AcelRx Pharmaceuticals in a research note on Monday, August 1st. They set a "sell" rating on the stock.